Kalm Therapeutics

Kalm Therapeutics is developing KP-77, a novel once-daily prescription patch designed to treat eczema and psoriasis. The patch combines physical skin protection with continuous, controlled delivery of a plant-based anti-inflammatory active ingredient, aiming to improve upon current messy creams and steroid treatments. The company is in the preclinical stage, targeting a significant unmet need in the dermatology market with a differentiated, patient-friendly product. Its approach leverages a proprietary drug delivery platform to create a therapeutic patch that addresses both symptom management and disease drivers like skin barrier dysfunction.

Proprietary transdermal patch technology for localized, continuous drug delivery combined with physical skin protection. Features a plant-based active ingredient and aims to support a balanced skin microbiome.

Kalm will compete in the broad topical dermatology market, facing off against generic corticosteroids, branded non-steroidal topicals (e.g., crisaborole, ruxolitinib cream), and systemic therapies. Its direct competition as a dedicated prescription patch is currently minimal, but it must demonstrate clear advantages over existing convenient formats like foams, sprays, and gels to gain adoption.